Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386458 | 0.84 | GPR84 (0.31) | — | |
| SCHEMBL152508 | 0.75 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL67474 | 0.73 | CYP1A2 (0.50) | CYP1A2 | |
| SCHEMBL249412 | 0.73 | ALDH1A1 (0.43) | CYP1A2HPRT1 | |
| SCHEMBL2333542 | 0.73 | ALDH1A1 (0.43) | CYP1A2HPRT1 | |
| SCHEMBL5747398 | 0.73 | CES2 (0.34) | — | |
| SCHEMBL5746771 | 0.73 | CA3 (0.33) | — | |
| SCHEMBL50091 | 0.71 | IDO1 (0.48) | CYP1A2 | |
| SCHEMBL18394230 | 0.71 | FFAR1 (0.31) | — | |
| SCHEMBL15452915 | 0.71 | CYP1A2 (0.31) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773586-B | Poly (fluorobenzene ester) polymer material and synthetic method thereof | 西安交通大学 | 2024-06-14 | — | — | CN | claimed |
| WO-2024027947-A1 | ANTICANCER AGENTS BASED ON CYCLOPENTENONES | UNIVERSITY OF CRETE (GR) | 2024-02-08 | — | — | WO | claimed |
| EP-4316476-A1 | ANTICANCER AGENTS BASED ON CYCLOPENTENONES | University of Crete (GR) | 2024-02-07 | — | — | EP | claimed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | claimed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | claimed |
| US-20230115208-A1 | RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF TUBERCULOSIS | QURETECH BIO AB (SE) | 2023-04-13 | — | — | US | claimed |
| CN-114773586-A | Poly (fluorophenyl ester) polymer material and synthesis method thereof | 西安交通大学 | 2022-07-22 | — | — | CN | claimed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | claimed |
| US-5866549-A | MACROLIDE ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1999-02-02 | — | — | US | claimed |
| US-5863924-A | Aryl pyrimidine derivatives | SYNTEX (U.S.A.) INC. (US) | 1999-01-26 | — | — | US | claimed |
| US-5804348-A | COLORLESS, METAL-FREE, IMPROVE CHARGE UNIFORMITY | EASTMAN KODAK COMPANY (US) | 1998-09-08 | — | — | US | claimed |
| US-5750305-A | Poly (2-(sulfonamidomethylene)-2-cyanoacetamido)phenyl acrylate! charge-control agents for electrostatographic toners and developers | EASTMAN KODAK COMPANY (US) | 1998-05-12 | — | — | US | claimed |
| WO-1998009978-A1 | 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 1998-03-12 | — | — | WO | claimed |
| WO-1997044326-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-27 | — | — | WO | claimed |
| US-5559154-A | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists | OREGON STATE BOARD OF HIGHER EDUCATION | 1996-09-24 | — | — | US | claimed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | claimed |
| US-5262568-A | Neuroprotective compounds, high binding affinity for phencyclidine, nervous system disorders | STATE OF OREGON (US) | 1993-11-16 | — | — | US | claimed |
| US-4112219-A | Acyl derivatives of antibiotic BM123γ | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115208-A1 | RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF TUBERCULOSIS | IL17A, TBCB, TBC1D15 | CYP1A2 247/4885HPRT1 715/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | CYP1A2 3777/4885HPRT1 2594/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | CYP1A2 2758/4885HPRT1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.